Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Posted: 11 December 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~…
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
Posted: 11 December 2023 Telix announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple negative breast cancer…
Game-Changing Research: Results from SVI’s BANDIT Type 1 Diabetes Trial
Posted: 11 December 2023 I am very proud to announce the results of our BANDIT trial – a world-first clinical trial investigating the use of an existing immunotherapy drug (baricitinib) to slow or stop the killing of insulin-producing…
Dedicated unit for CAR T and other cellular therapy patients opens at Peter Mac
Posted: 5 December 2023 A new dedicated treatment unit has opened at Peter Mac to care for patients receiving cell-based treatments, including CAR T-cell therapy. The unit, on Level 1 of Peter Mac’s main facility in Parkville, has…
2023 Neuren completes enrolment in Pitt Hopkins syndrome Phase 2 trial
Posted: 5 December 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Pitt Hopkins syndrome has been completed. Top-line results from the trial are expected to be…
BioCurate Board Announces Kathy Nielsen PhD M.Pharm M. IP. Law RTTP GAICD as New CEO
Posted: 5 December 2023 BioCurate, the independently operated joint venture between the University of Melbourne and Monash University, announced today it has appointed Dr. Kathy Nielsen to the role of Chief Executive Officer. Dr. Nielsen brings over 25…
Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
Posted: 5 December 2023 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Korean Ministry of Food and Drug Safety (MFDS) have approved the clinical trial to test narmafotinib (AMP945) in combination…
Gene linked to persistent stuttering into adulthood uncovered
Posted: 1 December 2023 A new study led by University of Melbourne researchers has discovered a link between a new gene pathway and structural brain anomalies in some people who stutter into adulthood, opening up promising research avenues to…
Exciting technology opens the door to new treatments for cancer and infectious diseases
Posted: 1 December 2023 Burnet Institute has entered into a Research Licence and Option Agreement with biopharma company argenx for a ground-breaking technology able to transform the way we approach cancer, inflammation and infectious disease treatment. Stellabody® is simple…
Cracking the code: researchers unravel how mutant protein drives cancer growth
Posted: 29 November 2023 WEHI researchers have solved a mystery about the most important driver of cancer development – a mutant protein found in half of all cancers – and how it contributes to tumour growth. The p53…
Platform Expansion: Lung Cancer Diagnostic Test Update
Posted: 29 November 2023 Rhythm Biosciences Ltd is pleased to provide an update on its cancer diagnostics technology platform expansion program in lung cancer. As previously announced, together with the Baker Institute, Rhythm has identified a 5 biomarker…
Japan’s Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Posted: 29 November 2023 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18…
